This is a preview of subscription content, log in via an institution to check access.
References
Duvic M., Hymes K., Heald P., et al. Phase II–III clinical trial of bexarotene capsules in patients with refractory advanced stage CTCL demonstrates efficacy and safety [abstract no. 60 & poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
Duvic M., Martin A., Kim Y., et al. Phase II–III clinical trial of bexarotene capsules demonstrates efficacy and safety for patients with refractory or persistent early stage CTCL [abstract no. 231 & poster]. American Academy of Dermatology 58th Annual Meeting; 2000 Mar 10–15; San Francisco
Heald P., Mehlmauer M., Martin A., et al. The benefits of topical bexarotene (Targretin ®) in patients with refractory or persistent early stage CTCL [abstract no. 545]. J Invest Dermatol 2000, 114: 840
Kuzel T., Breneman D., Duvic M., et al. Phase I–II trial of Targretin® gel in the topical treatment of patients with cutaneous T-cell lymphoma [abstract no. 536]. J Invest Dermatol 2000; 114: 839
Ligand Pharmaceuticals Targretin® (bexarotene) capsules, 75mg prescribing information. San Diego, California, USA, December 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, A.G. Bexarotene. Am J Clin Dermatol 1, 251–252 (2000). https://doi.org/10.2165/00128071-200001040-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001040-00008